AR054581A1 - Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion - Google Patents

Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion

Info

Publication number
AR054581A1
AR054581A1 ARP060103193A ARP060103193A AR054581A1 AR 054581 A1 AR054581 A1 AR 054581A1 AR P060103193 A ARP060103193 A AR P060103193A AR P060103193 A ARP060103193 A AR P060103193A AR 054581 A1 AR054581 A1 AR 054581A1
Authority
AR
Argentina
Prior art keywords
preparation
pharmaceutical compositions
weight
levetiracetam
include levetiracetam
Prior art date
Application number
ARP060103193A
Other languages
English (en)
Inventor
M Deleers
J B Hubert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054581(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of AR054581A1 publication Critical patent/AR054581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica que comprende levetiracetam como ingrediente activo y 2.0 a 9,0 % en peso de desintegrante; 0,0 a 3,0 % en peso de agente deslizante; 0,5 a 6,0% en peso de aglutinante, y 0,0 a 1,0 % en peso de lubricante, con respecto al peso total de la composicion farmacéutica, y a un proceso para su preparacion.
ARP060103193A 2005-07-26 2006-07-25 Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion AR054581A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05016189 2005-07-26
EP05016945 2005-08-04

Publications (1)

Publication Number Publication Date
AR054581A1 true AR054581A1 (es) 2007-06-27

Family

ID=36888840

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103193A AR054581A1 (es) 2005-07-26 2006-07-25 Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion

Country Status (26)

Country Link
US (1) US8802142B2 (es)
EP (1) EP1909764B1 (es)
JP (2) JP5183470B2 (es)
KR (1) KR20080030546A (es)
CN (1) CN101068534B (es)
AR (1) AR054581A1 (es)
AU (1) AU2006274263B2 (es)
BR (1) BRPI0606121A2 (es)
CA (1) CA2581831C (es)
CY (1) CY1115825T1 (es)
DK (1) DK1909764T3 (es)
EA (1) EA014961B1 (es)
ES (1) ES2524771T3 (es)
HK (1) HK1109071A1 (es)
HR (1) HRP20141185T1 (es)
IL (1) IL182375A0 (es)
MX (1) MX2007004294A (es)
NO (1) NO20071667L (es)
NZ (1) NZ554157A (es)
PE (2) PE20070216A1 (es)
PL (1) PL1909764T3 (es)
PT (1) PT1909764E (es)
RS (1) RS53690B1 (es)
SI (1) SI1909764T1 (es)
TW (1) TW200738280A (es)
WO (1) WO2007012439A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070095456A (ko) 2005-01-27 2007-09-28 알렘빅 리미티드 레베티라세탐의 서방형 제제
EP1810676B1 (en) * 2006-01-24 2008-11-12 Teva Pharmaceutical Industries Limited Levetiracetam formulations and methods for their manufacture
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN101422442A (zh) * 2008-12-09 2009-05-06 沈阳药科大学 左乙拉西坦渗透泵控释片及其制备方法
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
KR101640164B1 (ko) * 2009-01-29 2016-07-15 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
SG177360A1 (en) 2009-06-26 2012-02-28 Taris Biomedical Inc Implantable drug delivery devices and methods of making the same
CN102038657B (zh) * 2009-10-10 2015-04-15 浙江华海药业股份有限公司 左乙拉西坦片及其制备方法
CA2789307A1 (en) * 2010-03-29 2011-10-06 Hetero Research Foundation Stable pharmaceutical composition of imatinib
TR201011148A1 (tr) 2010-12-30 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Levetirasetam farmasötik bileşimleri.
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
CN102188420B (zh) * 2011-03-25 2013-04-10 华润赛科药业有限责任公司 一种左乙拉西坦的药物组合物及其制备方法
CN102895214B (zh) * 2012-10-25 2014-03-26 杭州朱养心药业有限公司 左乙拉西坦片剂的固体药物组合物
CN102871981B (zh) * 2012-10-25 2013-11-13 杭州朱养心药业有限公司 包含左乙拉西坦的片剂药物组合物
CN103127175B (zh) * 2013-02-22 2014-01-22 张晓光 一种抗癫痫药物及其制备方法
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
MX365513B (es) 2013-03-15 2019-06-06 Aprecia Pharmaceuticals LLC Forma de dosificacion de dispersion rapida que contiene levetiracetam.
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP3074004A2 (en) * 2013-11-29 2016-10-05 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
CN104666263B (zh) * 2015-02-09 2017-07-11 海南华益泰康药业有限公司 一种含有左乙拉西坦的片剂及其制备方法
AU2016268096B2 (en) * 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6630229B2 (ja) * 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN107913258A (zh) * 2016-10-09 2018-04-17 北京阜康仁生物制药科技有限公司 一种左乙拉西坦缓释片及其制备方法
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7264711B2 (ja) * 2019-04-26 2023-04-25 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法
CN117838643A (zh) * 2023-12-29 2024-04-09 山东力诺制药有限公司 一种吡拉西坦片及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPH07503859A (ja) * 1992-10-09 1995-04-27 ヴァイシス・インコーポレーテッド 挿入エレメントおよび増幅可能な核酸
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
PL357472A1 (en) 1999-12-01 2004-07-26 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
ES2242024T3 (es) * 2001-03-22 2005-11-01 Ucb, S.A. Uso de ciertas pirrolidonas sustituidas tales como piracetam en el tratamiento de enfermedades virales y otras enfermedades.
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
EP1625378A4 (en) 2002-12-03 2007-05-16 Ucb Sa METHOD OF IDENTIFYING AGENTS FOR THE TREATMENT OF CEREALS, NEUROLOGICAL DISEASES, ENDOCRINOPATHIES AND HORMONE DISEASES
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
EP1517893A2 (en) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
CN102166359A (zh) 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
KR20070095456A (ko) 2005-01-27 2007-09-28 알렘빅 리미티드 레베티라세탐의 서방형 제제

Also Published As

Publication number Publication date
CN101068534B (zh) 2011-09-07
EP1909764B1 (en) 2014-09-10
EA200700566A1 (ru) 2008-08-29
IL182375A0 (en) 2007-07-24
US8802142B2 (en) 2014-08-12
JP2013018786A (ja) 2013-01-31
NO20071667L (no) 2007-04-26
JP5183470B2 (ja) 2013-04-17
EP1909764A1 (en) 2008-04-16
CA2581831C (en) 2013-11-12
PE20100265A1 (es) 2010-04-21
KR20080030546A (ko) 2008-04-04
ES2524771T3 (es) 2014-12-12
MX2007004294A (es) 2008-03-11
BRPI0606121A2 (pt) 2009-10-06
HRP20141185T1 (hr) 2015-01-30
WO2007012439A1 (en) 2007-02-01
EA014961B1 (ru) 2011-04-29
HK1109071A1 (en) 2008-05-30
PL1909764T3 (pl) 2015-03-31
US20080269316A1 (en) 2008-10-30
SI1909764T1 (sl) 2015-01-30
DK1909764T3 (da) 2014-12-15
PE20070216A1 (es) 2007-03-27
CN101068534A (zh) 2007-11-07
TW200738280A (en) 2007-10-16
CA2581831A1 (en) 2007-02-01
JP2009502835A (ja) 2009-01-29
AU2006274263B2 (en) 2011-01-27
RS53690B1 (en) 2015-04-30
NZ554157A (en) 2010-12-24
PT1909764E (pt) 2014-12-18
CY1115825T1 (el) 2017-01-25
AU2006274263A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
CL2015001959A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
AR064614A1 (es) Producto combinado par controlar parasitos en animales
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
DOP2011000176A (es) Compuestos organicos
CL2009000555A1 (es) Compuestos derivados de tetramatos sustituidos espirociclicamente con 4'4'-dioxaespiro; procedimiento de preparacion; agente para combatir plagas y/o vegetaciones indeseadas que comprende dichos compuestos; su procedimiento de preparacion y uso; composiciones y su uso
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
EA201001440A1 (ru) Композиция, поглощающая кожный жир
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112014033117A2 (pt) composição pesticida e método para controlar pestes
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
DE602006009144D1 (de) Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
ME00955B (me) Kompozicija sa produženim oslobađanjem koja sadrži derivat somatostatina u mikročesticama
DK1893237T3 (da) Farmaceutisk sammensætning, der omfatter en organopolysiloxan ela-stomer og et solubiliseret aktivt stof
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
BRPI0719772A2 (pt) Compostos, composições fungicidas para combater fungos nocivos fitopatogênicos, agente, método para combater fungos nocivos fitopatogênicos, semente, uso dos compostos, e, composição farmacêutica.
DK1771180T3 (da) Sammensætninger i form af en spray, der omfatter en kombination af clobetasolpropionat og calcitriol, en alkoholfase og en oliefase
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
BR112012015170A8 (pt) Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor
AR060155A1 (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas
BRPI0507144A (pt) formulações em pó
CO6541608A2 (es) Formulación de empaque para evitar la insolubilidad de las composiciones que contienen quitosán

Legal Events

Date Code Title Description
FA Abandonment or withdrawal